<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058833</url>
  </required_header>
  <id_info>
    <org_study_id>SMCDIAST119023</org_study_id>
    <nct_id>NCT05058833</nct_id>
  </id_info>
  <brief_title>Prognostic Impact of Cardiac Diastolic Function and Coronary Microvascular Function</brief_title>
  <acronym>DIAST-CMD</acronym>
  <official_title>Prospective Registry Evaluating Prognostic Impact of Cardiac Diastolic Function and Coronary Microvascular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chosun University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangneung Asan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DIAST-CMD registry (Prognostic Impact of Cardiac Diastolic Function and Coronary&#xD;
      Microvascular Function) is prospective registry which enrolled patients who underwent&#xD;
      echocardiography, cnically-indicated invasive coronary angiography and comprehensive&#xD;
      physiologic assessments including fractional flow reserve (FFR), CFR, and IMR measurements&#xD;
      for at least 1 vessel from Samsung Medical Center. Patients with hemodynamic instability,&#xD;
      severe LV dysfunction (left ventricular ejection fraction&lt;40%), a culprit vessel of acute&#xD;
      coronary syndrome, severe valvular stenosis or regurgitation were excluded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac diastolic dysfunction refers to a condition in which abnormalities in mechanical&#xD;
      function are present during diastole and is an independent predictor of mortality, even in&#xD;
      patients with preserved left ventricular (LV) systolic function. Clinical manifestations of&#xD;
      cardiac diastolic dysfunction are also variable, from asymptomatic subclinical heart failure&#xD;
      to heart failure with preserved ejection fraction, angina or exercise intolerance without&#xD;
      significant epicardial coronary artery disease, or end-stage heart failure. Although its&#xD;
      pathophysiology remains incompletely understood, findings from clinical and pre-clinical&#xD;
      studies have suggested systemic endothelial dysfunction, oxidative stress, and coronary&#xD;
      microvascular dysfunction (CMD) could be important pathophysiologic mechanisms for cardiac&#xD;
      diastolic dysfunction.&#xD;
&#xD;
      In this regard, recent studies evaluated non-invasively measured coronary flow reserve (CFR)&#xD;
      from positron emission tomography (PET), cardiac magnetic resonance imaging (MRI), or Doppler&#xD;
      echocardiography, and presented the association of depressed global CFR with cardiac&#xD;
      diastolic dysfunction and higher risk of clinical events. The presence of CMD can be also&#xD;
      evaluated by invasive physiologic assessment using both CFR and index of microcirculatory&#xD;
      resistance (IMR). Previous studies presented CMD could be one of the major causes of angina&#xD;
      without significant epicardial coronary artery disease and an independent predictor of&#xD;
      adverse clinical events in patients with stable ischemic heart disease, acute myocardial&#xD;
      infarction (MI), or myocardial disease. Nevertheless, there has been limited study which&#xD;
      evaluated the association between cardiac diastolic dysfunction and CMD using invasive&#xD;
      physiologic indices and their prognostic implications, especially in non-MI patients without&#xD;
      significant coronary artery stenosis.&#xD;
&#xD;
      Therefore, we designed the current DIAST-CMD registry to evaluate 3 important clinical&#xD;
      questions as to whether: (1) cardiac diastolic dysfunction is significantly associated with&#xD;
      the presence of CMD; 2) both cardiac diastolic dysfunction and CMD are significantly&#xD;
      associated with long-term cardiovascular death; and 3) integration of both disease entities&#xD;
      would have incremental prognostic stratification in non-MI patients without significant&#xD;
      epicardial coronary artery disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>3 year</time_frame>
    <description>Cardiovascular death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause death</measure>
    <time_frame>3 year</time_frame>
    <description>all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>3 year</time_frame>
    <description>Myocardial infarction according to universal definition of MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>3 year</time_frame>
    <description>Any revascularization according to ARC definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>3 year</time_frame>
    <description>Major adverse cardiac events (MACEs, a composite of cardiovascular death, MI, and any revascularization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure admission</measure>
    <time_frame>3 year</time_frame>
    <description>Admission due to heart failure</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Microvascular Coronary Artery Disease</condition>
  <condition>Diastolic Dysfunction</condition>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Patients with cardiac diastolic dysfunction</arm_group_label>
    <description>Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with coronary microcirculatory dysfunction</arm_group_label>
    <description>Patients with coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.</description>
    <arm_group_label>Patients with cardiac diastolic dysfunction</arm_group_label>
    <arm_group_label>Patients with coronary microcirculatory dysfunction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Coronary flow reserve and index of microcirculatory dysfunction</intervention_name>
    <description>Coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).</description>
    <arm_group_label>Patients with cardiac diastolic dysfunction</arm_group_label>
    <arm_group_label>Patients with coronary microcirculatory dysfunction</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The DIAST-CMD registry (Prognostic Impact of Cardiac Diastolic Function and Coronary&#xD;
        Microvascular Function) is prospective registry which enrolled patients who underwent&#xD;
        echocardiography, cnically-indicated invasive coronary angiography and comprehensive&#xD;
        physiologic assessments including fractional flow reserve (FFR), CFR, and IMR measurements&#xD;
        for at least 1 vessel from Samsung Medical Center. Patients with hemodynamic instability,&#xD;
        severe LV dysfunction (left ventricular ejection fraction&lt;40%), a culprit vessel of acute&#xD;
        coronary syndrome, severe valvular stenosis or regurgitation were excluded.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who underwent clinically-indicated invasive coronary angiography&#xD;
&#xD;
          -  Patients who underwent comprehensive physiologic assessments&#xD;
&#xD;
          -  Patients who were evaluated by echocardiography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with unavailable echocardiography data&#xD;
&#xD;
          -  Patients with hemodynamic instability&#xD;
&#xD;
          -  Patients with severe LV dysfunction (LV ejection fraction&lt;30%)&#xD;
&#xD;
          -  Patients with severe valvular stenosis or regurgitation&#xD;
&#xD;
          -  Culprit vessel of acute coronary syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo Myung Lee, MD, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joo Myung Lee, MD, MPH, PhD</last_name>
    <phone>82-2-3410-2575</phone>
    <email>drone80@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seung Hun Lee, MD, PhD</last_name>
    <phone>82-2-3410-2575</phone>
    <email>lsh8602@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Iowa Carver College of Medicine, Iowa City, IA, USA</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Doosup Shin, MD</last_name>
      <email>doosup87@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chosun University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo Myung Lee, MD, MPH, PhD</last_name>
      <email>drone80@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>David Hong, MD</last_name>
      <email>hongdawi@naver.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Joo Myung Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>coronary microvascular dysfunction</keyword>
  <keyword>diastolic dysfunction</keyword>
  <keyword>coronary flow reserve</keyword>
  <keyword>index of microcirculatory resistance</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The decision of sharing IPD will be determined after discussion by executive committee of the current study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

